Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Morepen Laboratories Limited

Market Cap 18.52B 195M 168M 155M 145M 272M 276M 1.83B 714M 9.01B 731M 716M 31.21B P/E Ratio 2024
22.4x
P/E Ratio 2025 21.8x
Enterprise Value 18.52B 195M 168M 155M 145M 272M 276M 1.83B 714M 9.01B 731M 716M 31.21B EV / Sales 2024
1.27x
EV / Sales 2025 1.45x
Free-Float
57.31%
Yield 2024 *
-
Yield 2025 0.42%
1 day+6.11%
1 week+11.59%
Current month+15.82%
1 month+9.69%
3 months+25.09%
6 months+21.10%
Current year+22.13%
1 week 42.52
Extreme 42.52
51.8
1 month 39.9
Extreme 39.9
51.8
Current year 33.44
Extreme 33.44
51.8
1 year 33.44
Extreme 33.44
66.36
3 years 27.08
Extreme 27.08
100.8
5 years 23.65
Extreme 23.65
100.8
10 years 7.21
Extreme 7.21
100.8
Manager TitleAgeSince
Chief Executive Officer 62 01/02/1992
Director of Finance/CFO 59 03/04/2002
Compliance Officer 40 12/11/2018
Director TitleAgeSince
Chairman 62 01/02/1992
Director/Board Member 57 13/08/2019
Director/Board Member 57 13/08/2019
Change 5-day change 1-year change 3-year change Capi.($)
+6.11%+11.59%-25.56%+85.50% 271M
-1.54%+1.27%+41.10%+157.30% 1,035B
+0.69%+3.05%+53.11%+50.01% 574B
+1.01%-0.04%+18.04%+64.91% 397B
+0.58%+0.77%+21.19%+15.95% 324B
-0.85%-2.86%+22.05%+13.80% 281B
+0.44%+3.48%+24.48%+34.39% 278B
+1.66%+5.61%-44.67%-47.49% 193B
-0.21%+1.47%+19.32%+63.19% 191B
-0.55%-2.97%+11.84%+60.96% 156B
Average +0.77%+2.03%+14.09%+49.85% 343.02B
Weighted average by Cap. -0.12%+2.39%+28.27%+72.41%

Financials

2024 2025
Net sales 17.02B 179M 155M 143M 133M 250M 254M 1.68B 656M 8.28B 672M 658M 28.68B 18.12B 191M 165M 152M 142M 266M 270M 1.79B 698M 8.82B 715M 700M 30.53B
Net income 962M 10.12M 8.74M 8.05M 7.54M 14.12M 14.34M 95.07M 37.07M 468M 37.97M 37.16M 1.62B 1.18B 12.42M 10.72M 9.88M 9.25M 17.34M 17.6M 117M 45.5M 574M 46.6M 45.61M 1.99B
Net Debt 121M 1.27M 1.1M 1.01M 945K 1.77M 1.8M 11.92M 4.65M 58.67M 4.76M 4.66M 203M -928K -9.76K -8.43K -7.77K -7.27K -13.63K -13.84K -91.75K -35.77K -452K -36.64K -35.86K -1.56M
Logo Morepen Laboratories Limited
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Employees
1,814
Date Price Change Volume
12/06/26 50.16 +6.11% 816,998
11/06/26 47.27 -4.25% 707,246
10/06/26 49.37 +1.50% 2,181,408
09/06/26 48.64 +13.62% 1,773,568
08/06/26 42.81 -2.22% 218,386
  1. Stock Market
  2. Stocks
  3. 500288 Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!